METTL3 expression showed to be dramatically upregulated within prostatic carcinoma samples in comparison with normal control, according to The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) dataset (Fig. S4A) and Gene Expression Omnibus (GEO) dataset (GSE200879) (Fig. S4D). This evidence concerns the gene METTL3 and prostate adenocarcinoma.